Regeneron Pharmaceuticals PT Raised to $425.00 at Deutsche Bank (REGN)
Investment analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $410.00 to $425.00 in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Deutsche Bank’s price objective suggests a potential upside of 30.59% from the company’s current price.
The analysts wrote, “Eylea 2Q sales in the US were $415M vs. $410M consensus. In 1Q’14 the company did $359M in Eylea Us sales. Since 1Q’14 sales were impacted by weather and inventory this growth was expected in 2Q. The co reaffirmed 2014 full year guidance at $1.7-$1.8B. We note that this guidance means ~$925-$1025M sales in 2H’14 vs. ~$775M sales in 1H’14. Per our calc this suggests ~$50-$150M incremental sales in DME in 2H’14.”
A number of other firms have also recently commented on REGN. Analysts at Roth Capital raised their price target on shares of Regeneron Pharmaceuticals from $382.00 to $399.00 in a research note on Wednesday, July 30th. Separately, analysts at Argus initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $375.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $343.89.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 2.31% on Tuesday, hitting $332.96. 1,436,920 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $227.64 and a 52 week high of $352.49. The stock’s 50-day moving average is $303. and its 200-day moving average is $305.5. The company has a market cap of $32.866 billion and a price-to-earnings ratio of 93.30.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, August 5th. The company reported $2.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter last year, the company posted $1.73 earnings per share. Regeneron Pharmaceuticals’s revenue was up 45.4% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals will post $9.90 EPS for the current fiscal year.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.